The anti-tumor activity of the 7A7 antibody, specific to murine EGFR, is independent of target expression levels in immunocompetent mice

Biotecnologia Aplicada

Volumn 24, Issue 1, 2007, Pages 26-32

  Garrido, Greta ^a   Sánchez, Belinda ^a   Pérez, Rolando ^a   Fernández, Luis E ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Cancer therapy; Drug resistance; EGFR; Monoclonal antibodies; Predictive factor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 14; MONOCLONAL ANTIBODY; MONOLONAL ANTIBODY 7A7; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL MEMBRANE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG INHIBITION; EPITHELIUM TUMOR; FEMALE; IMMUNOCOMPETENCE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

MURINAE; MUS;

EID: 36249011867     PISSN: 08644551     EISSN: 10272852     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Normanno N, De Lucas A, Bianco C, et al. Epidermal growth factor-recptor (EGFR) signaling in cancer. Gene 2006;366:2-16.
2. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37 Suppl 4:S9-15.
3. Baselga J. New technologies in epidermal growth factor receptor-targeted cancer therapy. Signal 2000;1:12-21.
4. Crombet T, Osorio M, Cruz T, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004;22:1646-54.
5. Systems-ImClone, Erbitux (Cetuximab). US Prescribing Information. 2004, ImClone System: Princenton, NJ.
6. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol 2004;22:2610-6.
7. Lynch TJ, Lilenbaum R, Bonomi P, et al. A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004.
8. Boerner JL, Danielsen A, Maihle NJ. Ligand-independent oncogenic signaling by the epidermal growth factor receptor: v-ErbB as a paradigm. Exp Cell Res 2003;284:111-21.
9. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
10. Posadas EM, Liel MS, Kwitkowski V, et al. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 2007; (in press).
11. Pal SK, Pegram M. Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapy. Anticancer Drugs 2005;16:483-94.
12. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-99.
13. Garrido G, Sánchez B, Rodriguez HM, et al. 7A7 MAb: A New Tool for the Preclinical Evaluation EGFR-Based Therapies. Hybrid Hybridomics 2004;23.
14. Vazquez A, Alfonso M, Lanne B, et al. Generation of a murine monoclonal antibody specific for N-glycolyneuraminic acid-containing ganglosides that also recognizes sulfated glycolipid. Hybrid Hybridomics 1995;14:551-5.
15. Eisenbach L, Hollander N, Greenfeld L, et al. The differential expression of H-2K versus H-2D antigens, distinguishing high-metastatic from low-metastatic clones, is correlated with the immunogenic properties of the tumor cells. Int J Cancer 1984;34:567-73.
16. Honda J, Oomizu S, Kiuchi Y, et al. Identification of epidermal growth factor mRNA-expressing cells in the mouse anterior pituitary. Neuroendocrinology 2000;71:155-62.
17. Janmaat ML, Kruyt FA, Rodriguez JA, et al. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003;9:2316-26.
18. Saltz L, Meropol N, Lohher SP, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the EGFR. J Clin Oncol 2004;22:1201-8.
19. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patient with advanced NSCLC. J Clin Oncol 2003;12:2237-46.
20. Kris M, Natale R, Herbst R, et al. Efficacy of gefitinib, an inhibitor of the EGFR tyrosine kinase, in symptomatic patients with NSCLC: randomized trial. J Am Med Ass 2003; 290.
21. Cohen E, Rosen F, Stadler W, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21:1980-7.
22. Drucker B, Bacik J, Ginsberg M, et al. Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. Invest New Drugs 2003;21:341-5.
23. Rich J, Reardon D, Peery T, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004;22:133-42.
24. Goss G, Stewart D, Hirte H, et al. Initial results of part 2 of a phase I/II pharmacokinetics (PK), pharmacodynamic (PD) and bilogical activity study of ZD1839 (Iressa): NCIC CTG IND.122. Proc Am Soc Clin Oncol 2002:16a.
25. Giaccone G, Herbst R, Manegold C, et al. Gefitinib in combination with Gemcitabine and cisplatin in advanced NSCLC: a phase II trial-INTACT 1. J Clin Oncol 2004;22:777-84.
26. Herbst R, Giaccone G, Schiller G, et al. Gefitinib in combination with placlitaxel and carboplatin in advanced NSCLC. a phase III trial-INTACT 2. J Clin Oncol 2004;22:785-94.
27. Yang X, Jia X, Corvalan J, et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999;59:1236-43.
28. Yang XD, Jia XC, Corvalan JRF, et al. Development of ABX-EGF, a fukky human anti-EGFR monoclonal antibody, for cancer theraphy. Crit Rev Oncol Hematol 2001;38:17-23.
29. Vanhoefer U, Tewes M, Rojo F, et al. Phase I study of the humanized anti-EGFR Mab EMD 72000 in patients with advanced solid tumours that express the EGFR. J Clin Oncol 2004;22:175-84.
30. Hambek M, Solbach C, Schnuerch HG, et al. Tumor necrosis factor alpha sensitizes low EGFR-expressing carcinomas for anti-EGFR therapy. Cancer Res 2001;61:1045-9.
31. Goldstein N, Prewett M, Zuklys K, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Cancer Res 1995:1311-8.
32. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005;6:279-86.
33. Saltz L, Rubin M, Hochster H, et al. Acne-like rash predicts response in patients treated with cetuximab (IMC-225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Prom Am Soc Clin Oncol 2001;20:7A.
34. Perez-Soler R, Chachoua A, Huberman M, et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001:310a.
35. Sánchez B, Suárez E, Garrido G, et al. Active anti-metastatic immunotherapy in Lewis Lung Carcinoma with self EGFR extra cellular domain protein in VSSP adjuvant. Int J Cancer 2006;120 (in press).
36. Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002;62:200-7.
37. Bianco R, Shin I, Ritter CA, et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003;22:2812-22.
38. Camp ER, Summy J, Bauer TW, et al. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 2005;11:397-405.
39. Gelderman KA, Tomlinson S, Ross GD, et al. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol 2004;25:158-64.
40. van der Kolk LE, Grillo-Lopez AJ, Baars JW, et al. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001;115:807-11.
41. Junnikkala S, Jokiranta TS, Friese MA, et al. Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1. J Immunol 2000;164:6075-81.
42. Blok VT, Daha MR, Tijsma OM, et al. A possible role of CD46 for the protection in vivo of human renal tumor cells from complement-mediated damage. Lab Invest 2000;80:335-44.